MedTrace Logo

Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

NCT02949193 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2016-10-31

No results posted yet for this study

Summary

This is a randomized, double-blind, active-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

Conditions

Interventions

DRUG

evogliptin

evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg

DRUG

Sitagliptin

sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Sung Woo Park, M.D., Ph.D. · Kangbuk Samsung Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-11-30
Completion
2015-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02949193 on ClinicalTrials.gov